Related company info
Ingrid Lee, Taipei; Steve Shen, DIGITIMES
Thursday 11 October 2012
  • Apex Biotechnology
  • Performance
    The company's stock price closed at NT$31.2 on the TSE on Wednesday, April 18, 2018.
    The company has reported consolidated revenues of NT$147 million for March 2018, representing a 6.5% drop on month and 16% drop on year.
    For the fourth quarter of 2017, the company totaled NT$472 million in consolidated revenues, down 1.3% sequentially and up 27.9% on year.
    Brief

    Full name: Apex Biotechnology

    Chinese name: 五鼎生物技術股份有限公司

    Short name: Apex

    Stock code: 1733

    Tax ID: 16130182

    Market: TSE

    Established: 2 Dec 1997

    Paid in capital: NT$997.27 million

    Listed on TSE: 17 Sep 2001

    Website: www.apexbio.com

  • Latest stock
    Apex [1733] historical stock price (NT$)
    DateVolume (k)TransactionsValueOpenHighLowCloseChangeAskBid
    19-Apr 499 312 15,691,200 31.70 31.75 31.20 31.20+0.00+0.00% 31.20 31.45
    18-Apr 461 275 14,406,950 31.60 31.80 31.05 31.20-0.25-0.79% 31.20 31.30
    17-Apr 780 508 24,540,100 32.00 32.10 31.10 31.45-0.45-1.41% 31.40 31.45
    16-Apr 1,067 747 34,468,800 32.50 33.00 31.80 31.90+0.30+0.95% 31.90 32.00
    13-Apr 755 459 24,035,750 32.20 32.50 31.40 31.60-0.60-1.86% 31.60 31.70
    12-Apr 466 277 15,082,200 32.85 32.90 32.10 32.20-0.30-0.92% 32.20 32.30
    11-Apr 741 453 24,096,885 33.40 33.50 32.20 32.50+0.30+0.93% 32.45 32.50
    10-Apr 1,131 735 37,384,970 33.95 33.95 32.20 32.20-1.20-3.59% 32.20 32.35
    • Source: TSE, compiled by Digitimes
    Latest sales

    Apex: Consolidated revenues, Mar 2017 - Mar 2018 (NT$m)

    Month

    Sales

    M/M

    Y/Y

    YTD

    Y/Y

    Mar-18

    147

    (6.5%)

    (16%)

    476

    12%

    Feb-18

    158

    (8%)

    59.6%

    329

    31.7%

    Jan-18

    171

    9.5%

    13.5%

    171

    13.5%

    Dec-17

    156

    9.7%

    62.2%

    1,795

    1.8%

    Nov-17

    143

    (17.7%)

    3.2%

    1,639

    (1.7%)

    Oct-17

    173

    12.6%

    28.8%

    1,496

    (2.1%)

    Sep-17

    154

    5.4%

    17.5%

    1,323

    (5.1%)

    Aug-17

    146

    (18.4%)

    19.3%

    1,169

    (7.4%)

    Jul-17

    179

    16.7%

    19.1%

    1,024

    (10.3%)

    Jun-17

    153

    17.6%

    (4.5%)

    845

    (14.8%)

    May-17

    130

    (4.6%)

    (21.7%)

    692

    (16.7%)

    Apr-17

    136

    (22.2%)

    (25.2%)

    561

    (15.5%)

    Mar-17

    175

    77.6%

    (6.2%)

    425

    (11.8%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2018

    Apex: Consolidated revenues, 4Q16 - 4Q17 (NT$m)

    Quarter

    Sales

    Q/Q

    Y/Y

    YTD

    Y/Y

    4Q-17

    472

    (1.3%)

    27.9%

    1,795

    1.8%

    3Q-17

    478

    14%

    18.7%

    1,323

    (5.1%)

    2Q-17

    420

    (1.2%)

    (17.5%)

    845

    (14.8%)

    1Q-17

    425

    15.2%

    (11.8%)

    425

    (11.8%)

    4Q-16

    369

    (8.5%)

    (23.1%)

    1,763

    (4.6%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2018

    Latest balance sheet and income statement

    Apex: Consolidated balance sheet, 4Q16 - 4Q17 (NT$k)

    Item

    4Q-2017

    3Q-2017

    2Q-2017

    1Q-2017

    4Q-2016

    Current assets

    1,598,533

    1,576,999

    1,632,388

    1,647,085

    1,602,788

    Intangible assets

    294,089

    304,638

    314,386

    25,010

    25,854

    Non-current assets

    1,101,248

    1,124,705

    1,143,758

    880,663

    897,998

    Assets

    2,699,781

    2,701,704

    2,776,146

    2,527,748

    2,500,786

    Current liabilities

    1,018,272

    1,062,660

    818,230

    482,436

    414,574

    Non-current liabilities

    16,642

    17,492

    355,661

    354,649

    353,912

    Liabilities

    1,034,914

    1,080,152

    1,173,891

    837,085

    768,486

    Stockholders' equity

    1,664,867

    1,621,552

    1,602,255

    1,690,663

    1,732,300

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2018

    Apex: Consolidated income statement, 4Q16 - 4Q17 (NT$k)

    Item

    4Q-2017

    3Q-2017

    2Q-2017

    1Q-2017

    4Q-2016

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    Gross sales

     

     

    478,449

     

    419,801

     

    424,990

     

     

     

    Operating revenue

    472,060

    98.7%

    478,449

    100%

    419,801

    100%

    424,990

    100%

    368,972

    78.2%

    Gross profit (loss) from operations

    163,763

    34.2%

    102,951

    21.5%

    89,252

    21.3%

    75,548

    17.8%

    89,255

    18.9%

    Operating expenses

    84,407

    17.6%

    77,552

    16.2%

    47,662

    11.4%

    60,894

    14.3%

    56,217

    11.9%

    Operating income (loss)

    79,356

    16.6%

    25,399

    5.3%

    41,590

    9.9%

    14,654

    3.4%

    33,038

    7%

    Non-operating expenses and losses

    -18,114

    -3.8%

    3,629

    0.8%

    19,106

    4.6%

    -53,646

    -12.6%

    -144,637

    -30.6%

    Income from continuing operations before income tax

    61,242

    12.8%

    29,028

    6.1%

    60,696

    14.5%

    -38,992

    -9.2%

    -111,599

    -23.6%

    Net income (loss)

    43,611

    9.1%

    20,501

    4.3%

    57,277

    13.6%

    -38,992

    -9.2%

    -130,469

    -27.6%

    Diluted earnings per share (NT$)

    0.4

     

    0.2

     

    0

     

     

     

    0

     

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2018

  • Apex Biotechnology full profile
Realtime news

Global server market – 4Q 2017

Taiwan LCD monitors – 4Q 2017

Taiwan handsets – 4Q 2017

Global AP market, 2017-2021

Taiwan server shipment forecast and industry analysis, 2018

China AMOLED panel capacity expansion forecast, 2016-2020

© DIGITIMES Inc. All rights reserved.
Please do not republish, publicly broadcast or publicly transmit content from this website without written permission from DIGITIMES Inc. Please contact us if you have any questions.